Phaseline

Companies › Sandoz

Sandoz: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ocrelizumab (CYB704)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Relapsing Multiple SclerosisNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06847724Ocrelizumab (CYB704)Phase 3Relapsing Multiple SclerosisNeurologyNov 2026

From the company's SEC filings

Complete response letters from FDA

Targets

MS4A1 (1)

Companies with the same targets

Roche Biocad Acerta Pharma Regeneron Pharmaceuticals Celltrion TG Therapeutics Genmab Novartis AbbVie AstraZeneca

Companies built like this

Merz Pharmaceuticals Lupin Neurona Therapeutics Cytopeutics Sdn. Bhd. NKGen Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.